Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak
| Autor: | Sang Hyub Lee, Y. S. Cho, H. S. Seo, Woo Jin Lew, Hyungcheon Kim, E. J. Lee, Y. M. Lee, Jae-Joon Yim, Hyun Kyung Lee, Tae Sun Shim |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Tuberculosis Adolescent Epidemiology Antitubercular Agents Group Homes Tuberculin Disease Outbreaks Young Adult Latent Tuberculosis Internal medicine Republic of Korea medicine Humans Adverse effect Tuberculosis Pulmonary Aged business.industry Incidence (epidemiology) Outbreak Skin test Middle Aged bacterial infections and mycoses medicine.disease Infectious Diseases Immunology Female Rifampin business Rifampicin medicine.drug |
| Zdroj: | Epidemiology and Infection. 140:1028-1035 |
| ISSN: | 1469-4409 0950-2688 |
| Popis: | SUMMARYWe screened tuberculosis (TB) contacts as an outbreak investigation with tuberculin skin test (TST) and interferon-gamma release assay (IGRA). We evaluated adverse events and TB incidence in all persons screened after rifampicin (RFP) prophylaxis, and specifically assessed the new TB cases in relation to initial TST and IGRA results. The 180 contacts were divided into four groups: TST+/IGRA+ (n=101), TST+/IGRA− (n=22), TST−/IGRA+ (n=16), and TST–/IGRA– (n=41). RFP treatment (4 months) was prescribed only to the TST+/IGRA+ group. Of 87 contacts who initiated prophylaxis, adverse events occurred in 21 contacts (24·1%) including hepatotoxicity (11·5%), flu-like syndrome (5·7%), and thrombocytopenia (3·4%). TB developed in two TST+/IGRA+ subjects after completion of prophylaxis, including one multidrug-resistant (MDR)-TB case during 21·8 months of follow-up. Adverse events were frequent, and development of TB including MDR-TB occurred after RFP prophylaxis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|